# Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

> **NCT00324324** · PHASE3 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 240 (estimated)

## Conditions studied

- Breast Cancer
- Chronic Myeloproliferative Disorders
- Gestational Trophoblastic Tumor
- Infection
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Neuroblastoma
- Ovarian Cancer
- Testicular Germ Cell Tumor

## Interventions

- **DRUG:** moxifloxacin hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00324324
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2007-04
- **Final completion:** 2012-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00324324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00324324, "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00324324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*